HAMPTON, NH, December 8, 2021 /PRNewswire/ — Novalis LifeSciences LLC, an investment and advisory firm for the life sciences industry, today announced that it has raised $300 million in capital for his second fund – Novalis LifeSciences Investments II, LP. In addition, Paul M. Meister joined the firm as a partner.

Novalis LifeSciences focuses on highly innovative life sciences companies. On the occasion of the closing of the second fund, Marijn E. Dekkers, Founder and Chairman, said: “This second fund will continue the investment strategy of Fund I. It will invest in 10 to 15 companies that commercialize cutting-edge technologies in various segments of the life science industry.” These segments include biopharmaceutical therapeutics, life science tools, genomics, synthetic biology, molecular diagnostics and agricultural biotechnology – all areas with huge unmet needs and exciting opportunities for investors. Some key Fund I portfolio companies are Ginkgo Bioworks, Cerevel Therapeutics, Decipher Biosciences, Quanterix and Biotalys, all of which have recently gone public or been acquired.

Marijn Dekkers continued: “I am also delighted to announce that Paul Meister joined the Novalis team as a partner. In his former role as Vice President at Fisher Scientific, Paul and I worked closely together to create Thermo Fisher Scientific through the merger of Thermo Electron and Fisher Scientific in 2006. With Paul’s extensive background in life sciences , I look forward to working with him again. on this second fund. In addition, two other new key members recently joined Novalis. They are Constantine G. Pantelis as Chief Operating Officer, and Seer Leak as general manager. For their background, please see www.novalislifesciences.com

About Novalis LifeSciences

Novalis LifeSciences LLC is an investment and advisory company founded in 2017 by Marijn E. Dekkers. With a team of experienced operational executives from the life sciences industry, Novalis finances and advises visionary life science entrepreneurs. The company has approximately $500 million under management in two investment funds.

SOURCE Novalis LifeSciences LLC